Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dillon, Read & Co. was a prominent American investment bank that operated as a top-tier financial institution for much of the 20th century. While not a biotechnology or pharmaceutical company itself, the firm was a major player in the financial landscape, providing underwriting, advisory, and M&A services to various industries, including healthcare and life sciences. The firm was known for its prestigious reputation and its role in significant corporate restructurings and capital raises. In 1997, the company was acquired by Swiss Bank Corporation (SBC), which subsequently merged with Union Bank of Switzerland to form UBS. Today, the legacy of Dillon Read is integrated into the global operations of UBS Investment Bank.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Dillon Read & Co..